menu
    • menu

    Company profile for Shanghai Henlius Biotech

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a global biopharmaceutical company focusing on oncology and auto-immune diseases with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built three global R&D facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Shanghai Henlius BiotechChina Flag
    Country
    Country
    China
    Address
    Address
    9/F, Innov Tower, Zone A, No. 1801 Hongmei Road, Xuhui District, Shanghai
    Telephone
    Telephone
    021-33395800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.henlius.com/en/Index.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Supply Chain Ties, Bayer Biotech Incubator—Fierce Pharma Asia
    Supply Chain Ties, Bayer Biotech Incubator—Fierce Pharma Asia

    21 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fierce-pharma-asia-us-china-supply-chain-ties-bayer-biotech-incubator-henlius-biosim-nod

    FIERCE PHARMA
    21 Nov 2025
    Share Share
    FDA Approves POHERDY® as First PERJETA Biosimilar
    FDA Approves POHERDY® as First PERJETA Biosimilar

    17 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117955804/en/Henlius-and-Organon-Announce-US-FDA-Approval-of-POHERDY-pertuzumab-dpzb-the-First-PERJETA-pertuzumab-Biosimilar-in-the-US

    BUSINESSWIRE
    17 Nov 2025
    Share Share
    Shanghai Henlius’s Biologics Poherdy Receives Approval In US
    Shanghai Henlius’s Biologics Poherdy Receives Approval In US

    13 Nov 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761450

    FDA
    13 Nov 2025
    Share Share
    Forlong Biotech In Collaboration With Henlius For Cancer
    Forlong Biotech In Collaboration With Henlius For Cancer

    22 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251022986359/en/Forlong-Biotechology-Announces-Collaboration-Agreement-with-Henlius-to-Develop-Innovative-Cancer-Immunotherapy-with-an-Engineered-Cytokine

    BUSINESSWIRE
    22 Oct 2025
    Share Share
    HANSIZHUANG Ph3 Trial Meets Goal in Gastric Cancer, NDA Planned
    HANSIZHUANG Ph3 Trial Meets Goal in Gastric Cancer, NDA Planned

    09 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/phase-3-clinical-trial-of-hansizhuang-plus-chemotherapy-meets-primary-endpoint-in-neoadjuvantadjuvant-gastric-cancer-greenlighting-early-nda-submission-302579700.html

    PR NEWSWIRE
    09 Oct 2025
    Share Share
    EC Approves Henlius, Organon's BILDYOS & BILPREVDA Biosimilars
    EC Approves Henlius, Organon's BILDYOS & BILPREVDA Biosimilars

    19 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-19/european-commission-ec-approves-henlius-and-organon-s-bildyos-denosumab-and-bilprevda-denosum

    PHARMAWEB
    19 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search